Thomasian Harry Jr. sold $1.1M of PGEN

Thomasian Harry Jr. (Chief Financial Officer) sold 200,000 shares of PRECIGEN, INC. (PGEN) at an average of $5.57 ($5.53–$5.78, $1.11M total) across 2 trades over 2026-06-29 to 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Thomasian Harry Jr.
Published Jul 1, 2026, 10:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 1, 2026, 10:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PGEN
Neutral
medium confidence
Mentioned
$PGEN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PGENNeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider selling size, timing, and average sale price, but it does not include new operational, financial, or regulatory information.

02

Market read

Use the filing to update sentiment/positioning around PGEN, but expect limited fundamental read-through absent additional catalysts.

03

What to watch

Traders may overreact to insider sales; the key nuance here is the 10b5-1 structure and the relatively small dollar amount versus typical institutional flows.

Relevance 5/10Novelty 5/10Timing: filed after-hours on 2026-07-01; reflects sales executed 2026-06-29 to 2026-07-01

Background

This is an SEC Form 4 insider transaction disclosure for Precigen, Inc. (PGEN).

Company-level read

Ticker impact

$PGENNeutralMedium confidence
Context

Precigen CFO Thomasian Harry Jr. sold about 200,000 shares in open-market transactions totaling ~$1.11M under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect would be incremental and fade unless paired with other negative news.

Evidence & confidence

The filing is primary-source (Form 4) and quantifies size/price, but it is explicitly under a 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide driver.

None indicated.

None indicated.

Counterpoint

Because the trades were executed under a pre-arranged 10b5-1 plan, the sale may reflect routine liquidity needs rather than a bearish view on fundamentals.

Key entities

  • PRECIGEN, INC.

    Subject of the Form 4 insider transaction disclosure.

  • Thomasian Harry Jr.

    Chief Financial Officer who sold shares in open-market transactions.

  • 10b5-1 plan

    Pre-arranged plan noted as Yes, which can reduce interpretive signal.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PGENHighAI 9/10

PGEN Stock Crashes Premarket: Retail Sees Buyout Opening As Inovio Rival Crashes The Party Before Earnings

Precigen (PGEN) shares dropped 20% premarket after Inovio's (INO) FDA-approved rival treatment, Voceryq, challenged Papzimeos. PGEN reported $53.1M Q2 revenue. Retail investors remain optimistic about a potential buyout. Voceryq expects shipments in 60 days, with full deployment in early 2027. Clinical trials showed higher surgery-free rates for Papzimeos (51%) vs. Voceryq (27%).

$INOHighAI 9/10

FDA Grants Accelerated Approval to Inovio's DNA Immunotherapy Voceryq; Precigen Shares Plunge 27% After Hours

FDA granted accelerated approval to Inovio's (INO) DNA immunotherapy Voceryq for recurrent respiratory papillomatosis. Inovio shares surged 300% after hours, while Precigen's (PGEN) shares dropped 27% on market competition concerns. Voceryq is the first plasmid DNA-based immunotherapy approved in the U.S. and the second treatment for the disease.

$PGENMedAI 8/10

Precigen (PGEN) Gets FDA Recognition. Can it Cut the Cost of Developing New Drugs?

Precigen (PGEN) received FDA Platform Technology Designation for AdenoVerse, the technology behind PAPZIMEOS. The designation may reduce development costs for future drugs, including PRGN-2009, an investigational cancer treatment. Management expects benefits but has not quantified cost savings or timelines. The FDA's draft guidance outlines potential benefits, but Precigen must provide supporting evidence for reuse of prior data. Hedge fund sentiment showed a slight decrease in holdings.

$PGENHighAI 8/10

Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform

Precigen, Inc. (PGEN) announced that the FDA granted platform technology designation to its AdenoVerse® immunotherapeutic platform, used in its commercial product PAPZIMEOS®. This designation may accelerate the development of future therapies by leveraging existing data and reducing duplicative work. The company's CEO highlighted the potential benefits for its clinical portfolio, including PRGN-2009 for HPV-associated cancers.

$MRNAHighAI 9/10

After Moderna’s Big News, Here Are Three Biotechs to Watch

Moderna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.